Dr Reddy’s Laboratories has launched Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer). 

Carboprost Tromethamine Injection is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion:

  • Failure of expulsion of the fetus during the course of treatment by another method;
  • Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity;
  • Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus;
  • Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.

It is also approved for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.

Related Articles

The approval was designated a Competitive Generic Therapy, meaning the Company will have 180-day exclusivity to market the product. 


Continue Reading

For more information visit drreddys.com.